174 related articles for article (PubMed ID: 29402806)
1. Gastric Neuroendocrine Tumors (G-Nets): Incidence, Prognosis and Recent Trend Toward Improved Survival.
Yang Z; Wang W; Lu J; Pan G; Pan Z; Chen Q; Liu W; Zhao Y
Cell Physiol Biochem; 2018; 45(1):389-396. PubMed ID: 29402806
[TBL] [Abstract][Full Text] [Related]
2. Incidence and survival trends for gastric neuroendocrine neoplasms: An analysis of 3523 patients in the SEER database.
Cao LL; Lu J; Lin JX; Zheng CH; Li P; Xie JW; Wang JB; Chen QY; Lin M; Tu RH; Huang CM
Eur J Surg Oncol; 2018 Oct; 44(10):1628-1633. PubMed ID: 29983275
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival.
Halfdanarson TR; Rabe KG; Rubin J; Petersen GM
Ann Oncol; 2008 Oct; 19(10):1727-33. PubMed ID: 18515795
[TBL] [Abstract][Full Text] [Related]
4. Increasing incidence of duodenal neuroendocrine tumors: Incidental discovery of indolent disease?
Fitzgerald TL; Dennis SO; Kachare SD; Vohra NA; Zervos EE
Surgery; 2015 Aug; 158(2):466-71. PubMed ID: 26013986
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological features and prognosis of patients with gastric neuroendocrine tumors: A population-based study.
Tian FX; Cai YQ; Zhuang LP; Chen MF; Xiu ZB; Zhang Y; Liu H; Liu ZH; Liu GP; Zeng C; Lin FL; Liu J; Huang ST; Zhang LZ; Lin HY
Cancer Med; 2018 Nov; 7(11):5359-5369. PubMed ID: 30311450
[TBL] [Abstract][Full Text] [Related]
6. Best prognostic factor of neuroendocrine tumors: Grade or Stage? A multidisciplinary single-center study.
Özaslan E; Bayram F; Karaca H; Gürsoy Ş; Öztürk F; Sözüer E; Abdurrezzak Ü; Yurci A; Can Sezgin G; Yıldırım A; Başpınar O; Kula M; Özkan M
Turk J Gastroenterol; 2016 Nov; 27(6):509-514. PubMed ID: 27852541
[TBL] [Abstract][Full Text] [Related]
7. Malignant neuroendocrine tumors: incidence and outcomes in pediatric patients.
Allan B; Davis J; Perez E; Lew J; Sola J
Eur J Pediatr Surg; 2013 Oct; 23(5):394-9. PubMed ID: 23444065
[TBL] [Abstract][Full Text] [Related]
8. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
Mosquera C; Koutlas NJ; Fitzgerald TL
Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
[TBL] [Abstract][Full Text] [Related]
9. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis.
Madani A; Thomassen I; van Gestel YRBM; van der Bilt JDW; Haak HR; de Hingh IHJT; Lemmens VEPP
Ann Surg Oncol; 2017 Aug; 24(8):2199-2205. PubMed ID: 28204963
[TBL] [Abstract][Full Text] [Related]
10. [Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: good prognosis with early detection].
Scherübl H; Faiss S; Jahn HU; Liehr RM; Schwertner C; Steinberg J; Stölzel U; Weinke T; Zimmer T; Klöppel G
Dtsch Med Wochenschr; 2009 Jul; 134(30):1529-35. PubMed ID: 19603370
[TBL] [Abstract][Full Text] [Related]
11. Clinical and prognostic features of rectal neuroendocrine tumors.
Weinstock B; Ward SC; Harpaz N; Warner RR; Itzkowitz S; Kim MK
Neuroendocrinology; 2013; 98(3):180-7. PubMed ID: 24080744
[TBL] [Abstract][Full Text] [Related]
12. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
Dasari A; Shen C; Halperin D; Zhao B; Zhou S; Xu Y; Shih T; Yao JC
JAMA Oncol; 2017 Oct; 3(10):1335-1342. PubMed ID: 28448665
[TBL] [Abstract][Full Text] [Related]
13. Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States.
Lee MR; Harris C; Baeg KJ; Aronson A; Wisnivesky JP; Kim MK
Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2212-2217.e1. PubMed ID: 30580091
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems?
Scherübl H; Cadiot G; Jensen RT; Rösch T; Stölzel U; Klöppel G
Endoscopy; 2010 Aug; 42(8):664-71. PubMed ID: 20669078
[TBL] [Abstract][Full Text] [Related]
15. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.
Halperin DM; Shen C; Dasari A; Xu Y; Chu Y; Zhou S; Shih YT; Yao JC
Lancet Oncol; 2017 Apr; 18(4):525-534. PubMed ID: 28238592
[TBL] [Abstract][Full Text] [Related]
16. A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress.
Modlin IM; Champaneria MC; Chan AK; Kidd M
Am J Gastroenterol; 2007 Jul; 102(7):1464-73. PubMed ID: 17391319
[TBL] [Abstract][Full Text] [Related]
17. Predicting Survival and Response to Treatment in Gastroesophageal Neuroendocrine Tumors: An Analysis of the National Cancer Database.
Gray KD; Moore MD; Panjwani S; Elmously A; Afaneh C; Fahey TJ; Zarnegar R
Ann Surg Oncol; 2018 May; 25(5):1418-1424. PubMed ID: 29476295
[TBL] [Abstract][Full Text] [Related]
18. Differing Clinical Courses and Prognoses in Patients With Gastric Neuroendocrine Tumors Based on the 2010-WHO Classification Scheme.
Kim BS; Park YS; Yook JH; Oh ST; Kim BS
Medicine (Baltimore); 2015 Nov; 94(44):e1748. PubMed ID: 26554772
[TBL] [Abstract][Full Text] [Related]
19. Epidemiologic trends in neuroendocrine tumors: An examination of incidence rates and survival of specific patient subgroups over the past 20 years.
Sackstein PE; O'Neil DS; Neugut AI; Chabot J; Fojo T
Semin Oncol; 2018 Aug; 45(4):249-258. PubMed ID: 30348533
[TBL] [Abstract][Full Text] [Related]
20. Survival of Patients With Gastroenteropancreatic Neuroendocrine Tumors and Diabetes Mellitus.
Thapi S; Baeg K; Kim MK; Gallagher EJ
Pancreas; 2021 Oct; 50(9):1293-1297. PubMed ID: 34860814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
